MINNEAPOLIS, Jan. 24, 2017 /PRNewswire/ -- In a major
study released this weekend from the University Hospital Muenster,
Germany1
(http://www.multivu.com/players/English/7899551-nephrocheck-test-acute-kidney-injury-outcomes/),
Astute Medical's CE marked and FDA cleared NephroCheck® Test
identified patients at high risk of Acute Kidney Injury (AKI) after
open heart surgery. In this randomized control trial led by
Alexander Zarbock, M.D., those
patients identified received either the institution's standard of
care or a treatment per Kidney Disease Improving Global Outcomes
(KDIGO) guidelines (http://kdigo.org/home/guidelines). For the
first time, there is now evidence that early recognition of AKI
risk combined with clinically guided treatments reduces the
occurrence of moderate to severe AKI by more than 33%, a
substantial improvement over current standard of care.
"We congratulate our colleagues at Astute Medical and their
clinical collaborators on the release of this significant study,"
said Charles R. Kummeth, President
and Chief Executive Officer at Bio-Techne. "We are strong advocates
for protein biomarkers as important tools in diagnostics. However,
it is only through studies like the one reported here that we can
gauge the true value of a test's ability to impact patients and
overall healthcare costs. The results here are nothing short of
stunning! We're excited about our current and future
collaborative projects, adding to the Astute140® test menu and
allowing the Astute Medical development team access to our vast
content catalogue of potential biomarkers."
More information on the NephroCheck® Test for risk assessment of
AKI can be found at:
http://www.multivu.com/players/English/7899551-nephrocheck-test-acute-kidney-injury-outcomes/
On December 14, 2016, Bio-Techne
announced a strategic partnership with Astute Medical that included
an equity investment by Bio-Techne. The partnership was
structured to allow Bio-Techne to build a strategic foundation in
diagnostics, with an option to further expand the relationship.
(https://www.bio-techne.com/press-releases/press/20161214)
1 Meersch M, Schmidt C, Hoffmeier A, et al.
Prevention of cardiac surgery-associated AKI by implementing the
KDIGO guidelines in high risk patients identified by biomarkers:
The PreAKI randomized controlled trial. Intensive Care Med.
Open access online. 2017.
ABOUT BIO-TECHNE CORPORATION:
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences
company providing innovative tools and bioactive reagents for the
research and clinical diagnostic communities. Bio-Techne products
assist scientific investigations into biological processes and the
nature and progress of specific diseases. They aid in drug
discovery efforts and provide the means for accurate clinical tests
and diagnoses. With thousands of products in its portfolio,
Bio-Techne generated approximately $499
million in net sales in fiscal 2016 and has approximately
1,650 employees worldwide. For more information on Bio-Techne and
its brands, please visit www.bio-techne.com.
Intended Use and Indications for the NephroCheck®
Test System:
The NephroCheck® Test System is intended to be used in
conjunction with clinical evaluation in patients who currently have
or have had within the past 24 hours acute cardiovascular and or
respiratory compromise and are ICU patients as an aid in the risk
assessment for moderate or severe acute kidney injury (AKI) within
12 hours of patient assessment. The NephroCheck® Test
System is intended to be used in patients 21 years of age or
older.
Forward-Looking Statements
Our press releases may contain forward-looking statements within
the meaning of the Private Securities Litigation Reform Act. Such
statements involve risks and uncertainties that may affect the
actual results of operations. Forward-looking statements in
this press release include statements regarding our belief about
the market applications and impact of our investment in and
collaboration with Astute Medical, Inc. and our ability to
derive advantages from this investment. The following
important factors, among others, have affected and, in the future
could affect, the actual results: our management of investments in
and acquisitions of new businesses into Bio-Techne, the effect of
new branding and marketing initiatives, the introduction and
acceptance of new products, the levels and particular directions of
research and product development by our customers, general economic
conditions, the impact of currency exchange rate fluctuations, and
the costs and results of our research and product development
efforts and those of companies in which we have invested or with
which we have formed strategic relationships. For additional
information concerning such factors, see the section titled "Risk
Factors" in the Company's annual report on Form 10-K and quarterly
reports on Form 10-Q as filed with the Securities and Exchange
Commission. We undertake no obligation to update or revise any
forward-looking statements we make in our press releases due to new
information or future events. Investors are cautioned not to place
undue emphasis on these statements.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/bio-techne-congratulates-astute-medical-on-clinical-trial-results-300395917.html
SOURCE Bio-Techne Corporation